From Multivalency to Biomarker-Guided Delivery: Integrating Breakthroughs for the Future of Targeted Protein Degradation
Recent advances in targeted protein degradation combine dual E3 ligase-recruiting multivalent PROTACs, Survivin as a predictive biomarker for therapeutic responsiveness, and dendrimer-PROTAC conjugates for CNS and inflammation-targeted delivery. Together, these innovations form a synergistic framework for potent, selective, and biomarker-guided degraders with enhanced delivery, offering a promising blueprint for next-generation therapeutics in oncology and beyond.
Authors
- Mahmoud A. Elkhalifa
- Robert B. Kargbo (ORCID: https://orcid.org/0000-0002-5539-6343)
Institutions
- California University of Pennsylvania (US)
- Usona Institute (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00734
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00